“Medical device coverage is shrinking among financial outlets,” began Chris Gale, SVP for EVC Group, a San Francisco and New York-based investor relations and public relations firm for medical device companies.
An evolving FDA process may be contributing indirectly to the shrinking coverage.
“Venture capitalists are not investing in new medical technology firms and bigger companies are wrestling with stagnating markets. VCs are leery of the US medical device market right now, primarily because of the FDA process being perceived as more challenging.”
Read on for a major medical device marketing and sales implication.
View the story “Reaching physicians and investors.”
Most of EVC Group’s clients are small and mid-cap companies and the majority of those are in medical technology including AngioDynamics, Uroplasty, Delcath Systems, and TeleFlex. (PS: I worked with Chris extensively when I was Director of Marketing Communications for Cardiac Science Corporation.)